Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors

6 Apr 2024

Abstract excerpt

gene transfer as illustrated by the approvals of 7 drugs across Europe and the United States. Nevertheless, preexisting immunity to AAV capsid in humans remains one of the major limits for a successful clinical translation. Whereas a preexisting humoral response to AAV capsid is well documented, the prevalence of preexisting capsid-specific T cell responses still needs to be studied and characterized. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38581431
DOI: 10.1089/hum.2023.225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy DonorsPMID 38581431Read ↗

Prevalence study of cellular capsid-specific immune responses to AAV2, 4, 5, 8, 9 and rh10 in healthy donorsSemantic proximity Read ↗

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy DonorsSemantic proximity Read ↗

Exposure to wild-type AAV drives distinct capsid immunity profiles in humansSemantic proximity Read ↗

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialSemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Human Immune Responses to Adeno-Associated Virus (AAV) VectorsSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.Semantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving ControversySemantic proximity Read ↗

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene TransferSemantic proximity Read ↗

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.